Changeflow GovPing Healthcare & Life Sciences ModernaTX IL12 Polypeptide Patent EP3625246A1
Routine Rule Added Final

ModernaTX IL12 Polypeptide Patent EP3625246A1

Favicon for changeflow.com EPO Patent Bulletin - Pharma (A61K)
Published
Detected
Email

Summary

The EPO published patent application EP3625246A1 for polynucleotides encoding tethered interleukin-12 (IL12) polypeptides, filed by ModernaTX, Inc. The application names Ankita Mishra, Joshua Frederick, and Sushma Gurumurthy as inventors, with IPC classifications C07K 14/54 and A61K 38/20. The publication covers 35 designated contracting and extension states including major European markets. Pharmaceutical and biotechnology companies developing interleukin-based therapeutics should review this publication for potential freedom-to-operate implications in the European market.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 72 changes logged to date.

What changed

The EPO published patent application EP3625246A1 filed by ModernaTX, Inc. covering polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and their therapeutic uses. The application designates 35 European states including major markets such as Germany, France, the United Kingdom, Italy, and Spain.

Pharmaceutical and biotechnology companies engaged in IL-12 or interleukin-based therapeutic development should review this publication for potential freedom-to-operate concerns in European markets. Competitors with overlapping patent portfolios may need to assess design-around options or consider licensing discussions.

Archived snapshot

Apr 25, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

POLYNUCLEOTIDES ENCODING TETHERED INTERLEUKIN-12 (IL12) POLYPEPTIDES AND USES THEREOF

Publication EP3625246A1 Kind: A1 Apr 15, 2026

Applicants

ModernaTX, Inc.

Inventors

MISHRA, Ankita, FREDERICK, Joshua, GURUMURTHY, Sushma

IPC Classifications

C07K 14/54 20060101AFI20181123BHEP A61K 38/20 20060101ALI20181123BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Rule
Branch
International
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent examination Biopharmaceutical research
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!